| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced the results as published in the American Journal of Ophthalmology ("AJO") International of the large scale, comparative real-world clinical outcomes study of patients treated by three leading, minimally invasive glaucoma surgery ("MIGS") technologies.
Using the American Academy of Ophthalmology IRIS® Registry (Intelligent Research in Sight), the largest specialty society clinical data registry in all of medicine and the first comprehensive eye disease clinical registry in the United States, this large-scale MIGS study evaluated long-term 2-year post-surgical outcomes among patients with primary open-angle glaucoma ("POAG") treated with the three most commonly used FDA-approved/cleared ab interno MIGS devices in the U.S. (OMNI Surgical System ("OMNI"), Hydrus® Microstent, and iStent inject®) combined with cataract surgery, as well as for cataract surgery alone.
OMNI facilitates a unique implant-free, ab interno procedure that comprehensively addresses the three primary areas of resistance in the conventional outflow pathway. OMNI technology has been cleared by the FDA for canaloplasty followed by trabeculotomy to reduce intraocular pressure in adult patients with primary open-angle glaucoma.
Posted In: SGHT
